Investigational drug · Phase 3
Lunsekimig
Also called: SAR443765
Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
9
6 still active
All registered trials
9
Any phase or sponsor naming "Lunsekimig"
First trial start
2023
Oct 16, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Lunsekimig", any sponsor or status.
Conditions studied
As listed on its trial records.
- Asthma
- Chronic Obstructive Pulmonary Disease
- Chronic Rhinosinusitis With Nasal Polyps
- Dermatitis Atopic
Approved drugs for the same conditions: Asthma · COPD · Respiratory · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "Lunsekimig" as an intervention, largest first.
- A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingEnrolling by invitation
SanofiSanofi (SNY)
NCT07793409 · 1,508 participants (planned) · Start Sep 16, 2026 · Primary completion Jul 23, 2031
Drug: Lunsekimig · For: Chronic Obstructive Pulmonary Disease
Sites: Newport Beach, California; Boynton Beach, Florida; Miami, Florida · 16 sites in all
- Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic PhenotypePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07190222 · 942 participants (planned) · Start Sep 17, 2025 · Primary completion Nov 27, 2029
Drug: Lunsekimig; Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Birmingham, Alabama; Mobile, Alabama; Tucson, Arizona · 314 sites in all
- Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic PhenotypePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07190209 · 942 participants (planned) · Start Sep 16, 2025 · Primary completion Nov 27, 2029
Drug: Lunsekimig; Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Chandler, Arizona; Phoenix, Arizona; Surprise, Arizona · 322 sites in all
- Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With AsthmaEnrolling by invitation
SanofiSanofi (SNY)
NCT06609239 · 900 participants (planned) · Start Sep 30, 2024 · Primary completion Jan 20, 2031
Drug: Lunsekimig · For: Asthma
Sites: Chandler, Arizona; Tucson, Arizona; Aurora, Colorado · 150 sites in all
- Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe AsthmaPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT06102005 · 685 participants · Start Oct 16, 2023 · Primary completion Feb 23, 2026
Drug: Lunsekimig; Placebo · For: Asthma
Sites: Scottsdale, Arizona; Yuma, Arizona; Lancaster, California · 156 sites in all
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk AsthmaPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT06676319 · 556 participants · Start Nov 7, 2024 · Primary completion Jun 21, 2027
Drug: Lunsekimig; Short-Acting Beta Agonists (SABA) and 4 more · For: Asthma
Sites: Saraland, Alabama; Chandler, Arizona; Sun City, Arizona · 221 sites in all
- A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic DermatitisPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT06790121 · 150 participants · Start Jan 30, 2025 · Primary completion Feb 12, 2026
Drug: Lunsekimig; Placebo · For: Dermatitis Atopic
Sites: Encino, California; Sacramento, California; Thousand Oaks, California · 52 sites in all
SanofiSanofi (SNY)
NCT06454240 · 79 participants · Start Jul 17, 2024 · Primary completion Jan 29, 2026
Drug: lunsekimig; placebo · For: Chronic Rhinosinusitis With Nasal Polyps
Sites: La Jolla, California; Roseville, California; San Diego, California · 29 sites in all
- Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical StudyActive, not recruiting
SanofiSanofi (SNY)
NCT06914908 · 71 participants · Start May 12, 2025 · Primary completion Feb 22, 2029
Drug: Lunsekimig; Mometasone furoate nasal spray (MFNS) · For: Chronic Rhinosinusitis With Nasal Polyps
Sites: La Jolla, California; Roseville, California; Boise, Idaho · 24 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The dawn of the dual-target era in respiratory disease: promise, pitfalls, and a roadmap for bispecific antibodies.
Cheng Y, Ding J, Li Z, et al. · Front Immunol 2026
- Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?
Kourid MI, Couillard S · Eur Respir J 2025
- A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule.
Deiteren A, Krupka E, Bontinck L, et al. · Eur Respir J 2025
- A first-in-human, single and multiple dose study of lunsekimig, a novel anti-TSLP/anti-IL-13 NANOBODY® compound, in healthy volunteers.
Deiteren A, Bontinck L, Conickx G, et al. · Clin Transl Sci 2024
- Investigational thymic stromal lymphopoietin inhibitors for the treatment of asthma: a systematic review.
Rogliani P, Manzetti GM, Bettin FR, et al. · Expert Opin Investig Drugs 2024
Also in development for Asthma
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- GSK5784283Phase 38 trials
GSK · Pulmonary Disease, Chronic Obstructive, Asthma, Nasal Polyps
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- SHR-1905Phase 36 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Asthma, Chronic Rhinosinusitis With Nasal Polyps, Moderate-to-severe Atopic Dermatitis
- TozorakimabMEDI3506Phase 36 trials
AstraZeneca · Chronic Obstructive Pulmonary Disease (COPD), Asthma, Viral Lung Infection and Acute Respiratory Failure
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- BFFBFF MDI 320, BFF MDI 160Phase 34 trials
AstraZeneca · Asthma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.